Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 25, 2007 Brian Lawler	Flamel Gets Upbeat News About Coreg Flamel Technologies is earning more than had been calculated from its lead drug, but the company still isn't profitable. Investors, take note.
The Motley Fool August 3, 2007 Brian Lawler	Flamel Cooked When a drugmaker's future is highly dependent on one product, shares are bound to take a hit if that product isn't living up to expectations. Such was the case with Flamel Technologies.
The Motley Fool February 11, 2008 Brian Lawler	No Fire Fueling Flamel's Top Drug Flamel Technologies had a rough 2007; and with only one drug determining its near-term success, investors should be cautious of this drugmaker.
The Motley Fool August 24, 2007 Brian Lawler	Flamel Under Fire Stocks fall when study fails to show drug's superiority. Investors, take note.
The Motley Fool May 14, 2007 Brian Lawler	Just the Beginning for Flamel? The drug developer released first-quarter financial results and updated investors on the progress of its newly marketed Coreg CR compound. Investors, take note.
The Motley Fool March 5, 2008 Brian Lawler	Flamel in a Nutshell After a choppy year, Flamel says there are plenty of new possibilities in its pipeline.
The Motley Fool August 27, 2007 Rich Duprey	Flamel Falls Out of Compliance Market lashes out after a patient-compliance study shows that its only drug offers no better solution. Flamel has always been a risky investment, and that hasn't changed.
The Motley Fool December 18, 2006 Brian Lawler	Nice: Flamel's Drug Approval With so much pessimism and internal hullabaloo, there weren't many investors willing to stick with Flamel, but those who did have been rewarded nicely.
The Motley Fool August 8, 2008 Brian Lawler	Flamel Tries to Get It in Gear Flamel has done a good job of reducing its cash burn, allowing it to buy some time to work on the compounds in its pipeline.
The Motley Fool November 2, 2007 Brian Lawler	Flamel Plays Close to the Vest With only one sustainable source of revenue, the drug developer tries to curtail spending and get new compounds into the pipeline. Investors, take note.
The Motley Fool April 28, 2008 Brian Lawler	Flamel Inches Forward New sales data arrives for one lead drug, new promising data for another.
The Motley Fool May 15, 2008 Brian Lawler	What's Cooking at Flamel? The drugmaker makes finding partners to help pay for its hepatitis C and diabetes compounds a top priority.
The Motley Fool September 14, 2007 Brian Lawler	Is Flamel Catching On? Flamel Technologies announces a deal with Wyeth to develop an improved formulation of a drug, but the financials, and details, remain secret.
The Motley Fool October 26, 2007 Brian Lawler	Another Prospect for Flamel The drug developer's good week continues with favorable news about a treatment for hepatitis C. Investors, take note.
The Motley Fool July 26, 2007 Brian Lawler	Glaxo Getting Through Avandia Loss Glaxo's earnings aren't hurt by the decline in Avandia sales. When excessive fears start to bring down shares of a drugmaker with good sales-growth potential over the long run, smart investors should see a buying opportunity.
The Motley Fool October 25, 2007 Brian Lawler	Rope-a-Dope at GSK? Following the negative FDA panel hearings and safety review of diabetes drug Avandia and exchange rate movements against it, revenue fell 3% in the third quarter for GlaxoSmithKline. Operating income and profit were also slightly down.
The Motley Fool October 25, 2005 Jason Mac Gurn	Visualizing Value for Flamel Those interested in the long-term potential of this biotech's business should be searching for signs that its technological potential will evolve to provide value for shareholders.
Chemistry World July 16, 2010 Matt Wilkinson	Bittersweet victory for GSK's Avandia GlaxoSmithKline has received a muted 'thumbs up' from a US regulatory advisory panel for its much-maligned Type 2 diabetes drug Avandia (rosiglitazone), making it likely the US Food and Drug Administration will allow the UK-based pharma giant to continue selling the drug in the US.
The Motley Fool January 19, 2011 Cliff D'Arcy	Glaxo Stung by Legal Bill GSK shareholders are hit by costly legal settlements.
Chemistry World September 24, 2010 Andrew Turley	End of the road for Avandia? The European Medicines Agency has decided the troubled diabetes drug should be pulled from the market while the US Food and Drug Administration has said it will 'significantly restrict' its use.
The Motley Fool June 14, 2007 Brian Lawler	Dueling Fools: GlaxoSmithKline Bull Shares of the pharmaceutical may be temporarily down, but it's not out.
The Motley Fool November 15, 2007 Brian Lawler	Flamel Now Part of Wacky Lawsuit Hijinks Multiple class action shareholder lawsuits targeting Flamel Technologies are announced, following a failed study of the company's lead drug.
The Motley Fool April 28, 2005 Stephen D. Simpson	Glaxo Works to Stay on Track With FDA issues near resolution, Glaxo should continue its respectable growth trajectory. Investors looking at the pharmaceutical space would do well to at least consider this stock.
The Motley Fool November 3, 2011 Frank Vinluan	GSK Settles With Uncle Sam for $3B GSK said the settlement will reduce financial uncertainty for the company and is in the best interest of shareholders.
The Motley Fool April 29, 2010 Brian Orelli	Earnings Up 17%, but Here's Why You Should Be Worried One-time sales are no way to run a pharmaceutical business.
Chemistry World February 26, 2010 Sarah Houlton	Report hits out at GSK's Avandia GlaxoSmithKline's diabetes drug Avandia (rosiglitazone) has been dealt another blow, with the publication of a report by two US senators claiming the company knew about safety problems long before they reached the public domain.
The Motley Fool July 31, 2007 Brian Lawler	Avandia Can Stay An FDA advisory panel votes to allow GlaxoSmithKline's top diabetes compound, Avandia, to remain on the market.
The Motley Fool March 15, 2011 Brian Orelli	Extending the Competition in Parkinson's Disease Impax's extended-release drug looks good.
The Motley Fool February 22, 2010 Brian Orelli	Warning: Avandia Could Cause Drool Among Trial Lawyers An unintended side effect of Glaxo's Avandia might be excessive salivation among trial lawyers. A 342-page report by the Senate Finance Committee is painting the diabetes drug in a not-so-great light.
The Motley Fool July 9, 2010 Brian Orelli	2 Days, 1 Blockbuster, Fate Unknown GlaxoSmithKline heads before a marathon two-day Food and Drug Administration advisory panel review of its diabetes drug Avandia.
The Motley Fool August 15, 2007 Billy Fisher	Adversity Continues for Avandia Avandia and Actos receive black box labels from the FDA. The two diabetes medications have been linked to an increase in heart failure.
The Motley Fool June 8, 2009 Brian Orelli	For the RECORD... Avandia's not going to make a comeback for GlaxoSmithKline.
The Motley Fool July 15, 2010 Brian Orelli	The Blockbuster Drug Survives Another Body Blow Avandia is still standing.
The Motley Fool June 15, 2005 Charly Travers	Flamel's CEO Must Go Because the biotech firm has disappointed, investors have understandably not rewarded its lousy results. Flamel's shareholders must vote to remove a management road block to the company's success.
The Motley Fool September 28, 2007 Brian Lawler	GSK Helps Secure Future of a Lead Drug GlaxoSmithKline settles a patent infringement case on a lead drug, Avandia, and with that challenger gone, the company is a step closer to securing one of its top franchises.
Pharmaceutical Executive July 30, 2007 Richard Altus	Avandia Sales Away What did you do when you heard the safety news about Avandia? Here's what the rest of the market did, and why it matters to you.
The Motley Fool April 10, 2008 Brian Lawler	Glaxo Angers the FDA GlaxoSmithKline announces that the FDA has sent it a warning letter regarding its failure to meet certain post-marketing requirements for Avandia.
The Motley Fool June 6, 2005 Rich Duprey	Flamel Inflames Passions The nanotech firm faces a fiery shareholder fight. Is Flamel doing enough to promote its medical technologies? Management says yes, but shareholders disagree. Here's a survey of the battlefield.
The Motley Fool October 26, 2006 Brian Lawler	Glaxo's Prescription for Sagging Sales Trading at roughly 32 times its trailing-12-month earnings, and with a solid 2.9% dividend yield, GSK is a fine investment for shareholders patient enough to wait until 2008 for a return to solid revenue growth.
The Motley Fool March 7, 2005 Brian Gorman	Glaxo in Hot Water Glaxo's problems with the FDA could have been avoided. Investors can only hope that the FDA is in a forgiving mood.
The Motley Fool September 6, 2007 Brian Lawler	Foolish Fantasy Football: GlaxoSmithKline on Defense In real life, defense wins championships. This stock analyst includes GlaxoSmithKline on his fantasy football investment team, to shield from a punishing sack by the market.
The Motley Fool June 3, 2011 Frank Vinluan	GSK Sees Positive Results on Asthma, COPD Drug Expected to Succeed Advair GSK gets good news.
The Motley Fool April 17, 2008 Brian Orelli	Headache Over for Pozen and Glaxo? The duo's FDA headache regarding their migraine drug is over, but a new one is about to begin.
The Motley Fool April 28, 2008 Brian Lawler	Glaxo Getting By Weakening currency barely redeems the pharmaceutical's Q1 numbers.
The Motley Fool June 12, 2007 Michael P. Cecil	When Dr. Nissen Talks ... Congress and the FDA listen. The Avandia story is just beginning, and drug-safety issues were hard on the share prices of Merck when Vioxx was in the news, as well as Pfizer when torcetrapib was taken off the market.
The Motley Fool September 15, 2006 Brian Lawler	Glaxo's Burgeoning Blockbuster With a deep drug pipeline filled with potential blockbusters for nearly every major disease, and an attractive 3% dividend yield, Glaxo makes a fine investment opportunity for investors willing to brave the pharmaceutical sector.
The Motley Fool July 26, 2006 Stephen D. Simpson	GlaxoSmithKline: Reliable, Dependable ... Kinda Boring This is a good-but-not-great pharmaceutical giant with a good-but-not-great valuation. Investors, take note.
Chemistry World July 31, 2007 Victoria Gill	FDA Advised: Avandia Should Stay on the Market The US Food and Drug Administration's (FDA's) Advisory Committee came to an almost unanimous decision yesterday for Avandia, GlaxoSmithKline's much-maligned diabetes treatment, to remain on the US market.
The Motley Fool May 22, 2007 Mike Havrilla	Avandia Safety Concerns Weigh Down Glaxo Shares of GlaxoSmithKline dropped nearly 8%, after a study raised safety concerns about the company's widely used diabetes drug, Avandia.
Chemistry World December 2, 2013 Lanay Tierney	US turnaround on Avandia restrictions Restrictions on the controversial diabetes medication Avandia (rosiglitazone) are to be lifted by the US Food and Drug Administration.